Syncom Formulations (India)

Price chart

Previous close

₹21.01

Open

₹20.80

Day high

₹21.26

Day low

₹20.35

Listed on NSE since 18 November 2022.

Market value

₹1,974.94 Cr

P/E (trailing)

22.35

EPS (trailing)

₹0.94

Price to book

4.72

Dividend yield

0.50%

Debt to equity

0.00

Profit margin

17.2%

Beta

0.93

Volume today

39.49 L

Average volume

1.94 Cr

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Syncom Formulations (India)’s results filed with NSE, consolidated (the whole group). Net profit is the share of Syncom Formulations (India)’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Syncom Formulations (India)’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, creams, liquids orals, and effervescent. Further, it provides liquid vials and ampoule injections, dry vial injections and inhalers; manufacturing and trading of nutraceuticals, dietary supplements, health supplements, functional foods, herbal and ayurvedic preparations, vitamins, minerals, proteins, antioxidants, natural extracts, organic and wellness products, and all related healthcare and nutrition-based goods and real estate business. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Indore

Employees

902

Company website · Profile: Yahoo Finance

No headlines name Syncom Formulations (India) in the last day or two.

• Dividend - Re 0.10 Per Share

  Dividend · ex-date 23 September 2026

• Annual General Meeting

  Action · ex-date 23 September 2024

• Annual General Meeting

  Action · ex-date 18 September 2023

Source: NSE. Latest first.